"This is one of our top picks, " says Joel Sendek, a biotech analyst at Lazard.

FORBES: Building An Antibiotic Powerhouse

Sendek expects wide use of Provenge, eventually, but worries that insurers could push back on price and rates the stock a hold.

FORBES

It is doubtful that Mr Sendek's hella campaign, which had almost 60, 000 supporters earlier this week, will be able to trump tradition.

ECONOMIST: Scientists measure a few yoctonewtons for the first time

Joel Sendek, an analyst at Lazard, is optimistic about AtheroGenics' chances but points out that the new trial is a big jump from the company's previous studies.

FORBES: Health

In a note to investors on May 25, Joel Sendek, a biotechnology analyst at Lazard Capital Markets, wrote that many physicians had been slow to start patients on Provenge as they figure out logistics and billing issues.

FORBES

Joel Sendek, an analyst at Lazard Capital Markets who says to sell Amgen's stock, argues that Mircera will still hurt Amgen internationally and that sales of anemia drugs are still going to be slower than Wall Street expects.

FORBES: Magazine Article